Article

25 Things About Me

Author(s):

Linnea Olson

I have stage 4 lung cancer. Here are 24 other things about me.

  1. I have stage 4 lung cancer; the histology is invasive mucinous adenocarcinoma.
  2. I was diagnosed when I was 45 years old.
  3. The youngest of my three children was seven.
  4. That was 10 years ago — it will be 11 years in April (woohoo!)
  5. My first line of treatment was a lower left lobectomy followed by four rounds of adjuvant chemotherapy.
  6. Staged at 1b initially, I was hoping I’d be cured.
  7. My cancer came back almost immediately.
  8. For two years, we watched and waited as there were no other viable treatments.
  9. By June 2008, I had more than 33 tumors in my lungs and a biopsy confirmed metastatic spread.
  10. I was told I had three to five months to live.
  11. This was one week before my daughter got married.
  12. Even though EGFR-negative, I started Tarceva (erlotinib) as a last ditch effort and began to say goodbye to family.
  13. At a scan review in September, it was clear that my cancer was spreading but there was good news.
  14. My biopsy showed that I was ALK-positive and a phase 1 trial targeting ALK mutations had just opened.
  15. On October 1, 2008, I became the fourth person in the world with NSCLC to take Xalkori (crizotinib).
  16. I felt better within days of regular dosing.
  17. My scan review six weeks later showed almost complete resolution of the cancer in my lungs.
  18. I took Xalkori for three years before progression forced me to switch therapies.
  19. I enrolled on another phase 1 clinical trial for Zykadia (ceritinib/LDK378) with similar results.
  20. This time, I got 18 months out of an experimental therapy.
  21. When I came off trial, I returned to chemotherapy again for six months and then I took a break.
  22. I went almost a year without treatment (glorious!) but I was also becoming more symptomatic.
  23. In May 2014, I enrolled into my third phase 1 clinical trial for PF-006463922/lorlatinib — once again I responded.
  24. My cancer has been stable for 18 months and I feel fabulous.
  25. I can’t wait to share more of my story with the readers of CURE!
Related Videos
Image of man with black hair.
Image of a man with dark hair and some facial hair.
Image of a man with blond facial hair.
Three women on a Zoom call discussing tracking side effects during breast cancer treatment.
Three women on a Zoom call discussing managing side effects of breast cancer treatment.
Three women on a Zoom call discussing managing side effects during breast cancer treatment.
Related Content
Image of prostate cancer scans.
November 22nd 2024

PSMA-Targeted Radiation Drug for Prostate Cancer Subset Meets Study Goal

Ryan Scott
Patients with PSMA-positive metastatic castration-resistant prostate cancer showed benefits after receiving PSMA-targeted treatment.
ROS1+ Non-Small Cell Lung Cancer: Progress in Care
September 20th 2024

ROS1+ Non-Small Cell Lung Cancer: Progress in Care

This episode of the Cancer Horizons podcast features Dr. Jason Porter – a medical oncologist and hematologist at the West Cancer Center and Research Institute and Director of the Lung Cancer Disease research group and is sponsored by Bristol Myers Squibb.
Illustration of a woman with long curly red hair.
November 22nd 2024

When Faced With a Cancer-Related Trigger

Linda Cohen
When I am triggered by something related to the cancer I have, I start going down a negative rabbit hole but remind myself to be vigilant when this happens.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Illustration of lungs.
November 22nd 2024

Magrolimab-Chemo Combo Improves Responses in Metastatic NSCLC

Ashling Wahner
Patients with metastatic non-small cell lung cancer and high CD47 expression showed improved responses to treatment with magrolimab plus docetaxel.
Subcutaneous Keytruda plus berahyaluronidase alfa meets phase 3 trial end points in non–small cell lung cancer.
November 21st 2024

Subcutaneous Keytruda Plus Berahyaluronidase Alfa Combo Meets Phase 3 Trial End Points in NSCLC

Ryan Scott
Treatment with subcutaneous Keytruda plus berahyaluronidase alfa meets phase 3 trial end points in the treatment of metastatic non–small cell lung cancer.